Oramed Pharmaceuticals Inc.(ORMP)Earnings, Financials & Key RatiosOramed Pharmaceuticals Inc. (ORMP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on non-operational equity gains to mask core business losses, combined with a cash position that has dropped from $84.8 million in 2024Q2 to $13.2 million in 2026Q1, suggests significant long-term execution risk.
Oramed Pharmaceuticals Inc. (ORMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Oramed Pharmaceuticals Inc. (ORMP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 19, 2026 | $0.16 | — |
| Q2 2026 | Mar 26, 2026 | $0.06vs $0.08+25.0% | —vs $500,000 |
| Q4 2025 | Nov 13, 2025 | $1.13vs $0.04+2925.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.05vs $0.04-25.0% | — |
Recent stock market news and headlines for Oramed Pharmaceuticals Inc. (ORMP)
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026) Oramed to Join the Russell 2000 and Russell 3000 Indexes this week NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026.
Key metrics vs top competitors for Oramed Pharmaceuticals Inc. (ORMP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.30 | $175.98M | 2.87 | — | 3202.5% | 37.12% | — | |
| $4.22 | $1.3B | 211.00 | 22.23% | -6.63% | — | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $49.64 | $220.59B | 14.10 | 6.43% | 37.2% | 66.36% | — | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — |
Oramed Pharmaceuticals Inc. (ORMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Oramed Pharmaceuticals Inc. (ORMP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Mar 31, 2026·SEC
Feb 20, 2026·SEC
Jan 14, 2026·SEC
Get notified when ORMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Oramed Pharmaceuticals Inc. (ORMP) stock FAQ — growth, dividends, profitability & financials explained
Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in revenue for fiscal year 2025.
Yes, Oramed Pharmaceuticals Inc. (ORMP) is profitable, generating $110.0M in net income for fiscal year 2025 (3202.5% net margin).
Oramed Pharmaceuticals Inc. (ORMP) has a return on equity (ROE) of 37.1%. This is excellent, indicating efficient use of shareholder capital.
Oramed Pharmaceuticals Inc. (ORMP) had negative free cash flow of $8.7M in fiscal year 2025, likely due to heavy capital investments.
